Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, announced last week that a clinical trial indicated that COVID-19 patients who receive remdesivir recover more quickly from the disease than those who did not receive the drug, Nature News reports. It notes, however, that another trial reported at the same time that there was no benefit from the drug.